Statins for Prevention of Disease Progression and Hospitalization in Liver Cirrhosis
Status:
Recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
In a randomized, doubleblind and placebo-controlled trial we assess both clinical and
cellular effects of atorvastatin in patients with liver cirrhosis.
162 participants will be allocated to atorvastatin 10-20 mg or placebo for 18 months.
Clinical outcomes of survival, hospitalizations and safety will be evaluated. Also, the trial
will investigate cellular functions in the liver by mass spectrometry proteomics, and single
cell transcriptomics as well as exploring atorvastatin effects on different fenotypes by
metagenomics.
Phase:
Phase 4
Details
Lead Sponsor:
Copenhagen University Hospital, Hvidovre
Collaborators:
Aarhus University Hospital Rigshospitalet, Denmark University of Copenhagen